Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine

Ok-Hyeon Kim,1 Jun Hyung Park,2 Jong In Son,1 Kyung-Yong Kim,1 Hyun Jung Lee1,2 1Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea; 2Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of KoreaCorre...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kim OH, Park JH, Son JI, Kim KY, Lee HJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	single-walled nanotubes parkinson’s disease intracranial intravenous nanomedicine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/753941b16e4642a8bedd21cb4ff953c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:753941b16e4642a8bedd21cb4ff953c7
record_format	dspace
spelling	oai:doaj.org-article:753941b16e4642a8bedd21cb4ff953c72021-12-02T10:21:46ZBoth Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine1178-2013https://doaj.org/article/753941b16e4642a8bedd21cb4ff953c72020-10-01T00:00:00Zhttps://www.dovepress.com/both-intracranial-and-intravenous-administration-of-functionalized-car-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Ok-Hyeon Kim,1 Jun Hyung Park,2 Jong In Son,1 Kyung-Yong Kim,1 Hyun Jung Lee1,2 1Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea; 2Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of KoreaCorrespondence: Hyun Jung LeeChung-Ang University, Rm615 Bd105, 84 Heuksuk-Ro, Dongjak-gu, Seoul 06974, Republic of KoreaTel +82-2-820-5434Email pluto38@cau.ac.krPurpose: Although single-walled nanotubes (SWNTs) with functional groups have been suggested as a potential nanomedicine to treat neuronal disorders, effective routes to administer SWNTs have not been compared thus far. The blood–brain barrier is a considerable challenge for the development of brain-targeting drugs, and therefore functionalized SWNT routes of administration have been needed for testing Parkinson’s disease (PD) treatment. Here, effective administration routes of functionalized SWNTs were evaluated in PD mouse model.Methods: Three different administration routes were tested in PD mouse model. Functionalized SWNTs were injected directly into the lateral ventricle three days before (Method 1) or after (Method 2) 6-hydroxydopamine (6-OHDA) injection to compare the protective effects of SWNTs against dopaminergic neuronal death or functionalized SWNTs were injected intravenously at three and four days after 6-OHDA injection (Method 3). Asymmetric behaviors and histological assessment from all animals were performed at two weeks after 6-OHDA injection.Results: Ventricular injections of SWNTs both before or after 6-OHDA exposure protected dopaminergic neurons both in the substantia nigra and striatum and alleviated rotational asymmetry behavior in PD mice. Moreover, intravenous administration of SWNTs three and four days after 6-OHDA injection also prevented neuronal death and PD mice behavioral impairment without apparent cytotoxicity after six months post-treatment.Conclusion: Our study demonstrates that functionalized SWNTs could effectively protect dopaminergic neurons through all administration routes examined herein. Therefore, SWNTs are promising nanomedicine agents by themselves or as therapeutic carriers to treat neuronal disorders such as PD.Keywords: single-walled nanotubes, Parkinson’s disease, intracranial, intravenous, nanomedicineKim OHPark JHSon JIKim KYLee HJDove Medical Pressarticlesingle-walled nanotubesparkinson’s diseaseintracranialintravenousnanomedicineMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 7615-7626 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	single-walled nanotubes parkinson’s disease intracranial intravenous nanomedicine Medicine (General) R5-920
spellingShingle	single-walled nanotubes parkinson’s disease intracranial intravenous nanomedicine Medicine (General) R5-920 Kim OH Park JH Son JI Kim KY Lee HJ Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
description	Ok-Hyeon Kim,1 Jun Hyung Park,2 Jong In Son,1 Kyung-Yong Kim,1 Hyun Jung Lee1,2 1Department of Anatomy and Cell Biology, College of Medicine, Chung-Ang University, Seoul, Republic of Korea; 2Department of Global Innovative Drugs, Graduate School of Chung-Ang University, Seoul, Republic of KoreaCorrespondence: Hyun Jung LeeChung-Ang University, Rm615 Bd105, 84 Heuksuk-Ro, Dongjak-gu, Seoul 06974, Republic of KoreaTel +82-2-820-5434Email pluto38@cau.ac.krPurpose: Although single-walled nanotubes (SWNTs) with functional groups have been suggested as a potential nanomedicine to treat neuronal disorders, effective routes to administer SWNTs have not been compared thus far. The blood–brain barrier is a considerable challenge for the development of brain-targeting drugs, and therefore functionalized SWNT routes of administration have been needed for testing Parkinson’s disease (PD) treatment. Here, effective administration routes of functionalized SWNTs were evaluated in PD mouse model.Methods: Three different administration routes were tested in PD mouse model. Functionalized SWNTs were injected directly into the lateral ventricle three days before (Method 1) or after (Method 2) 6-hydroxydopamine (6-OHDA) injection to compare the protective effects of SWNTs against dopaminergic neuronal death or functionalized SWNTs were injected intravenously at three and four days after 6-OHDA injection (Method 3). Asymmetric behaviors and histological assessment from all animals were performed at two weeks after 6-OHDA injection.Results: Ventricular injections of SWNTs both before or after 6-OHDA exposure protected dopaminergic neurons both in the substantia nigra and striatum and alleviated rotational asymmetry behavior in PD mice. Moreover, intravenous administration of SWNTs three and four days after 6-OHDA injection also prevented neuronal death and PD mice behavioral impairment without apparent cytotoxicity after six months post-treatment.Conclusion: Our study demonstrates that functionalized SWNTs could effectively protect dopaminergic neurons through all administration routes examined herein. Therefore, SWNTs are promising nanomedicine agents by themselves or as therapeutic carriers to treat neuronal disorders such as PD.Keywords: single-walled nanotubes, Parkinson’s disease, intracranial, intravenous, nanomedicine
format	article
author	Kim OH Park JH Son JI Kim KY Lee HJ
author_facet	Kim OH Park JH Son JI Kim KY Lee HJ
author_sort	Kim OH
title	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
title_short	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
title_full	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
title_fullStr	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
title_full_unstemmed	Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine
title_sort	both intracranial and intravenous administration of functionalized carbon nanotubes protect dopaminergic neuronal death from 6-hydroxydopamine
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/753941b16e4642a8bedd21cb4ff953c7
work_keys_str_mv	AT kimoh bothintracranialandintravenousadministrationoffunctionalizedcarbonnanotubesprotectdopaminergicneuronaldeathfrom6hydroxydopamine AT parkjh bothintracranialandintravenousadministrationoffunctionalizedcarbonnanotubesprotectdopaminergicneuronaldeathfrom6hydroxydopamine AT sonji bothintracranialandintravenousadministrationoffunctionalizedcarbonnanotubesprotectdopaminergicneuronaldeathfrom6hydroxydopamine AT kimky bothintracranialandintravenousadministrationoffunctionalizedcarbonnanotubesprotectdopaminergicneuronaldeathfrom6hydroxydopamine AT leehj bothintracranialandintravenousadministrationoffunctionalizedcarbonnanotubesprotectdopaminergicneuronaldeathfrom6hydroxydopamine
_version_	1718397349826396160

Both Intracranial and Intravenous Administration of Functionalized Carbon Nanotubes Protect Dopaminergic Neuronal Death from 6-Hydroxydopamine

Ejemplares similares